azlocillin (azlin) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Azlocillin is a semisynthetic penicillin with broad spectrum of anti-bacterial action. The drug is effective against gram-negative and gram-positive infections and acts by inhibition of penicillin-binding protein (PBP)-dependent bacterial cell wall synthesis. Azlocillin was marketed in the USA under the name Azlin (sodium salt), however, its approval was discontinued.   NCATS

Chemistry

  • SMILES: CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](NC(=O)N3CCNC3=O)c3ccccc3)C(=O)N2[C@H]1C(=O)O
  • InChIKey: JTWOMNBEOCYFNV-NFFDBFGFSA-N
  • Mol. Mass: 461.5
  • ALogP: 0.09
  • ChEMBL Molecules:
    azlocillin  
    azlocillin sodium  
More Chemistry

Pharmacology

Alternative names

(2s,5r,6r)-3,3-dimethyl-7-oxo-6-{[(2r)-2-{[(2-oxoimidazolidin-1-yl)carbonyl]amino}-2-phenylacetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid | azli | azlin | azlocilina | azlocillin | azlocilline | azlocillin sodium | azlocillin sodium salt | azlocillinum | securopen

Organizations (9)

Research & Development (8)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (6)

Approved Indications (1)


 

Bacterial Infections (approved 1982)

Experimental Indications - Clinical Trial Phases 1-4 (5)


 

Bronchiectasis (Phase 3)

Burkholderia Infections (Phase 3)

Cystic Fibrosis (Phase 3)

Pseudomonas aeruginosa (Phase 3)

Respiratory Tract Infections (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 11
  • # of Trial Organizations: 8

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue